Idiopatic angioedema treated with dapsone

Allergologia et Immunopathologia

Volumn 33, Issue 1, 2005, Pages 54-56

  Gonzalez P ^a   Soriano, V ^a   Caballero, T ^b   Niveiro, E ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antihistamines; Complement; Dapsone; Glucocorticoids; Glucose 6 phosphate dehydrogenase; Idiopathic angioedema; Sulfone

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; DAPSONE;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; CLINICAL FEATURE; FIBER OPTICS; HUMAN; IDIOPATHIC DISEASE; LABORATORY DIAGNOSIS; LARYNX EDEMA; MALE; PRICK TEST; RISK FACTOR;

EID: 16444377610     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070610     Document Type: Article

References (8)

1. Frigas E, Nzeako C. Angioedema. Clin Rev Allergy Immunol 2002;23:217-31.
2. Cicardi M, Bergamaschini I, Cugno M, et al. Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology 1998;199:366-76.
3. Agostini A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992;71:206-15.
4. Fortson JS, Zone JJ, Hammond ME, et al. Hypocomplementemic urticarial vasculitis syndrome responsive to dapsone. J Am Acad Dermatol 1986;15:1137-42.
5. Wolf R, Tuzun B, Tuzun Y, Dapsone: Unapproved uses or indications. Clin Dermatol 2000;18:37-53.
6. Stanaland B. Treatment of patients with chronic idiopathic urticaria. Clin Rev Allergy Immunol 2002;23:233-41.
7. Mc Evoy (ed.). AHFS drug information. Bethesda. American Society of Health-System Pharmacists. 2002; p. 831-6.
8. a ed. Ellenhorn M (ed.). Maryland. Williams and Wilkins 1997; p. 244.